Dapagliflozin Reduces Systolic Blood Pressure and Modulates Vasoactive Factors
Mechanisms underlying the improvements in blood pressure (BP) and congestive heart failure outcomes following treatment with dapagliflozin are not fully understood. We hypothesized that vasoactive mediators may be involved.